default author photo

Hongnan Mo

Tianjin Medical University - National Clinical Research Center for Cancer

Tianjin, 300060

China

  • Tianjin Medical University - National Clinical Research Center for Cancer

SCHOLARLY PAPERS

1

DOWNLOADS

20

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Safety and Efficacy Study of Oral Metronomic Capecitabine Combined with Pyrotinib in Her2-Positive Metastatic Breast Cancer: A Phase Ii Trial

Number of pages: 10 Posted: 22 Jun 2023
Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li and Binghe Xu
Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of VIP Medical Services, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer, Tianjin Medical University - National Clinical Research Center for Cancer and Chinese Academy of Sciences (CAS)
Downloads 20 (1,448,301)

Abstract:

Loading...

Phase II study, metastatic breast cancer, HER2-positive, pyrotinib, capecitabine, metronomic chemotherapy